tiprankstipranks
BerGenBio Partners with Tempus on Cancer Treatment
Company Announcements

BerGenBio Partners with Tempus on Cancer Treatment

BerGenBio ASA (BRRGF) has released an update.

Pick the best stocks and maximize your portfolio:

BerGenBio ASA has announced a collaboration with AI technology company Tempus to enhance the clinical development of its AXL inhibitor, bemcentinib, for treating Non-Small Cell Lung Cancer with STK11 mutations. The partnership will leverage real-world data and AI analytics from Tempus to establish a synthetic control group, aiming to improve treatment outcomes and set a new standard of care for this patient group. Excited leaders from both companies anticipate that the insights from this study will expedite the advancement of bemcentinib.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks European Auto-Generated NewsdeskBerGenBio Highlights Clinical Progress and Strategy
TipRanks European Auto-Generated NewsdeskBerGenBio ASA Appoints New CEO to Lead Growth
TipRanks Auto-Generated NewsdeskBerGenBio Reports Q3 2024 Earnings and Strategy Updates
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App